SCHEMBL17552002

SCHEMBL17552002

Cc1c(F)c(N)nc(N)c1F

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
NOS1 P29475 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7171640 0.86 LMNA (0.32) LMNA
SCHEMBL14997818 0.82 LMNA (0.39) LMNA
SCHEMBL23542846 0.80 LMNA (0.42) LMNA
SCHEMBL14997815 0.78
SCHEMBL6003760 0.76 REV1 (0.30)
SCHEMBL6409272 0.75 LMNA (0.32) LMNA
SCHEMBL10718494 0.71 LMNA (0.39) LMNA
SCHEMBL3670530 0.69 LMNA (0.41) LMNANOS1
SCHEMBL27929409 0.69 TLR8 (0.44) LMNANOS1
SCHEMBL20449075 0.69 LMNA (0.36) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116922004-A Manufacturing method of non-stick pan with wear-resistant antibacterial coating 宁波市金象厨具有限公司 2023-10-24 CN claimed
CN-116922004-A Manufacturing method of non-stick pan with wear-resistant antibacterial coating 宁波市金象厨具有限公司 2023-10-24 CN disclosed
EP-3186245-B1 MAPK INHIBITORS EverBrilliant Pharma Pty Ltd (AU) 2021-06-23 EP disclosed
US-20170266173-A1 MAPK INHIBITORS EVERBRILLIANT PHARMA PTY LTD. (AU) 2017-09-21 US disclosed
US-20170266173-A1 MAPK INHIBITORS EVERBRILLIANT PHARMA PTY LTD. (AU) 2017-09-21 US disclosed
WO-2016029263-A1 MAPK INHIBITORS WANG BING HUI (AU) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266173-A1 MAPK INHIBITORS MAPK1, MAPK4, MAPK3 LMNA 4686/4885NOS1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.